NCT01734395View on ClinicalTrials.gov

A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease

CompletedOBSERVATIONAL
Enrollment

1,882

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Alzheimer's Disease
Interventions
DRUG

Galantamine

This is an observational study. Galantamine 8 mg/day will be administered for the first 4 weeks and later on the dose will increased up to 24 mg (if tolerable). Galantamine dose will be adjusted according to the investigator's discretion.

All Listed Sponsors
lead

Janssen Korea, Ltd., Korea

INDUSTRY

NCT01734395 - A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease | Biotech Hunter | Biotech Hunter